title: Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics.
authors.forename: A
authors.initials: A
authors.lastname: Yoshikawa
authors.forename: M
authors.initials: M
authors.lastname: Nakada
authors.forename: S
authors.initials: S
authors.lastname: Ohtsuki
authors.forename: Y
authors.initials: Y
authors.lastname: Hayashi
authors.forename: W
authors.initials: W
authors.lastname: Obuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Sato
authors.forename: C
authors.initials: C
authors.lastname: Ikeda
authors.forename: T
authors.initials: T
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Kawahara
authors.forename: T
authors.initials: T
authors.lastname: Hasegawa
authors.forename: H
authors.initials: H
authors.lastname: Sabit
authors.forename: D
authors.initials: D
authors.lastname: Kita
authors.forename: Y
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Nakanuma
authors.forename: T
authors.initials: T
authors.lastname: Terasaki
authors.forename: J I
authors.initials: JI
authors.lastname: Hamada
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002851:Chromatography, High Pressure Liquid; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007211:Indoles / Q000627:therapeutic use*; D008577:Meningeal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008579:Meningioma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods*; D040901:Proteomics / Q000379:methods; D011758:Pyrroles / Q000627:therapeutic use*; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000032:analysis / Q000096:biosynthesis; D021241:Spectrometry, Mass, Electrospray Ionization; D000077210:Sunitinib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D020797:Receptor, Platelet-Derived Growth Factor beta; D000077210:Sunitinib